(Q39489743)

English

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 September 2017

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer (English)

1 reference

Europe PubMed Central

12 September 2017

phase III clinical trial

0 references

Patrick Schöffski

6

object named as

Patrick Schöffski

1 reference

Europe PubMed Central

12 September 2017

Rossella Elisei

3

object named as

Rossella Elisei

1 reference

Europe PubMed Central

12 September 2017

5

object named as

Ezra E W Cohen

1 reference

Europe PubMed Central

12 September 2017

author name string

Steven I Sherman

1

1 reference

Europe PubMed Central

12 September 2017

Douglas O Clary

2

1 reference

Europe PubMed Central

12 September 2017

Martin J Schlumberger

4

1 reference

Europe PubMed Central

12 September 2017

Lori J Wirth

7

1 reference

Europe PubMed Central

12 September 2017

Milan Mangeshkar

8

1 reference

Europe PubMed Central

12 September 2017

Dana T Aftab

9

1 reference

Europe PubMed Central

12 September 2017

Marcia S Brose

10

1 reference

Europe PubMed Central

12 September 2017

language of work or name

0 references

publication date

15 August 2016

1 reference

Europe PubMed Central

12 September 2017

1 reference

Europe PubMed Central

12 September 2017

122

1 reference

Europe PubMed Central

12 September 2017

24

1 reference

Europe PubMed Central

12 September 2017

3856-3864

1 reference

Europe PubMed Central

12 September 2017

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

Medullary thyroid cancer: management guidelines of the American Thyroid Association

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

Medullary thyroid carcinoma: targeted therapies and future directions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic value of codon 918 (ATG-->ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

Vandetanib for the treatment of medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

Cabozantinib in progressive medullary thyroid cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

Familial medullary thyroid cancer: clinical aspects and prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

Oncogenic RET Kinase Domain Mutations Perturb the Autophosphorylation Trajectory by Enhancing Substrate Presentation In trans

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhanced MET Translation and Signaling Sustains K-Ras-Driven Proliferation under Anchorage-Independent Growth Conditions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30252

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.30252

1 reference

Europe PubMed Central

12 September 2017

release_hzbucznvy5dvngpxlmn7ltvffu

1 reference

https://api.fatcat.wiki/v0/release/hzbucznvy5dvngpxlmn7ltvffu

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

12 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39489743&oldid=1839048474"